“Lower risks alternative for adult smokers”
Philip Morris International (PMI) has welcomed a landmark decision by the U.S. Food and Drug Administration (FDA) authorizing the marketing of selected ZYN nicotine pouches as a lower-risk alternative for adult smokers who completely switch from combustible cigarettes.
The FDA’s Modified Risk Tobacco Product (MRTP) authorization allows PMI to communicate that scientific evidence shows adult smokers who switch entirely from cigarettes to certain ZYN nicotine pouches can significantly reduce their exposure to harmful chemicals associated with smoking. The authorization applies only to specific ZYN products and is intended for adult smokers and other adult nicotine users.
The decision represents another significant milestone in PMI’s global smoke-free transformation, reinforcing its long-term commitment to developing scientifically substantiated alternatives to conventional cigarettes.
“This authorization is an important milestone for tobacco harm reduction and reflects the strength of the scientific evidence supporting smoke-free alternatives for adults who would otherwise continue smoking,” said a Philip Morris International spokesperson.
“Our vision is to replace cigarettes with better alternatives as quickly as possible for adults who choose to continue using nicotine products.”speaking with S.A BUZZ
The FDA emphasized that while ZYN nicotine pouches present substantially lower risks than smoking combustible cigarettes, they are not risk-free. Nicotine remains addictive, and the products are intended exclusively for adults. The agency also stressed that non-smokers, youth, and people who do not use nicotine should not start using these products.
“The authorization does not mean these products are safe,” the FDA said. “Rather, the available scientific evidence demonstrates that completely switching from cigarettes to the authorized products significantly reduces exposure to harmful chemicals compared with continued smoking.”Speaking with S.A BUZZ
PMI has invested billions of dollars in developing smoke-free products as part of its strategy to transition away from combustible cigarettes. The company’s portfolio now includes heated tobacco products and nicotine pouches sold across numerous international markets.
Public health experts remain divided on the decision. Harm reduction advocates believe the authorization provides adult smokers with access to evidence-based information about less harmful alternatives, while others continue to call for strict regulation to prevent youth uptake and unintended nicotine initiation.
Industry analysts believe the FDA’s decision could further strengthen ZYN’s position in the rapidly expanding nicotine pouch category while encouraging broader regulatory discussions around tobacco harm reduction globally.
As countries continue exploring strategies to reduce smoking-related disease, the FDA’s authorization is expected to serve as a significant reference point for future regulatory decisions concerning smoke-free nicotine products…follow more on @sabuzz99 https://sabuzz.co.za @pmi